Two HCC subclone variants representing GRP78-overexpressing (Mahlavu and Hep J5) sublines and its non-expressing counterpart (SK-Hep-1) were used to compare their sensitivities toward a group of anti-cancer drugs including sorafenib, 5-fluorouracil (5-FU), and doxorubicin. The gene discussed is HSPA5; the disease is cancer.